Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 1/20 | 0.55 |
| ▸ | NPY4R | P50391 | 10/20 | 0.51 |
| ▸ | NPY1R | P25929 | 6/20 | 0.50 |
| ▸ | NPY2R | P49146 | 6/20 | 0.50 |
| ▸ | NPY5R | Q15761 | 6/20 | 0.50 |
| ▸ | REN | P00797 | 1/20 | 0.50 |
| ▸ | CCKBR | P32239 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19862397 | 0.95 | NPY4R (0.52) | OPRM1NPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL19862098 | 0.95 | NPY4R (0.52) | OPRM1NPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL18048887 | 0.95 | NPY4R (0.52) | OPRM1NPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL19862399 | 0.95 | NPY4R (0.52) | OPRM1NPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL19862401 | 0.94 | NPY4R (0.53) | OPRM1NPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL25867315 | 0.92 | CCKBR (0.50) | OPRM1NPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL25867236 | 0.92 | NPY4R (0.49) | OPRM1NPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL24146440 | 0.91 | OPRM1 (0.54) | OPRM1NPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL19861965 | 0.90 | NPY4R (0.51) | OPRM1NPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL22563329 | 0.90 | NPY4R (0.49) | OPRM1NPY4RNPY1RNPY2RNPY5R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230227499-A1 | PRODRUGS OF MITOCHONDRIA-TARGETING OLIGOPEPTIDES | STEALTH BIOTHERAPEUTICS INC. | 2023-07-20 | — | — | US | disclosed |
| US-20230227499-A1 | PRODRUGS OF MITOCHONDRIA-TARGETING OLIGOPEPTIDES | STEALTH BIOTHERAPEUTICS INC. | 2023-07-20 | — | — | US | disclosed |
| EP-4168424-A1 | PRODRUGS OF MITOCHODRIA-TARGETING OLIGOPEPTIDES | Stealth BioTherapeutics Inc. (US) | 2023-04-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230227499-A1 | PRODRUGS OF MITOCHONDRIA-TARGETING OLIGOPEPTIDES | PITRM1, NME4, PDF | OPRM1 1592/4885NPY4R 822/4885NPY1R 1075/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.